Welcome to the International Society for Vaccines

Skip to main content

Officers and Board Members 2024-2025

Submitted by admin on Fri, 12/22/2023 - 10:49
President

Linda Klavinskis

Title
Professor of Viral Immunology, King’s College London
Description

Linda S. Klavinskis, PhD, is Professor of Viral Immunology at King’s College London where her laboratory focuses on immunity to vaccination and virus infection. The goal is to understand and harness cross talk between dendritic cells and T cells, and use this knowledge to develop new and more effective vaccines. This work has led to deciphering an alternative mode of antigen presentation, termed ‘cross-dressing’ and unravelling mechanisms contributing to epitope selection and CD8 T-cell immunodominance. At the translational level, her lab has made contributions to the development of gene delivery systems for DNA and viral-mediated vaccination. More, recently she made inroads in understanding the biology of skin immunisation and developed a microneedle vaccine delivery platform. This has led to the new finding that skin immunisation activates cross talk with innate cells in epithelial barrier tissues to recruit effector CD8+ T-cells and can establish immune surveillance at the barrier tissues. During the COVID-19 pandemic her lab has focused on the role of innate immunity in the hyperinflammatory response in severe COVID-19 and applying therapeutic approaches. Her laboratory has co-authored over 100 peer-reviewed publications.

Professor Klavinskis currently serves as a member of the UK Medical Research Council’s Infection and Immunity Board. She also serves as Associate Editor of Frontiers in Mucosal Immunology and as an Editor of Frontiers in HIV and AIDS. She has served as President of the ‘Medical Research Club’, a prestigious London based biomedical society established 1891 with a focus in infection and immunity. She contributes to national and international peer review in vaccine sciences and as a consultant in industry. She has expertise in executive and senior management positions, including most recently as Vice Dean for Postgraduate Research (Life Sciences and Medicine) at King’s College London. She is a Fellow of the International Society for Vaccines and was elected a Fellow of the Royal College of Pathologists.

Linda Klavinskis has been an active member of the International Society for Vaccines since 2015 and is an elected ISV Fellow. Her service to the ISV includes, membership of the Executive Board since 2018 (where she has championed promoting opportunities for women and junior/early career researcher members in ISV activities); Secretary for the 2020-2021 term; and is President-elect for the 2022-2023 term.

She served as Co-Chair of the 2019 ISV Annual Congress in Ghent, playing a key role in identifying the Scientific Committee (SC) and planning the scientific program with the SC and also introduced further opportunities for junior researchers e.g. the “Bright Sparks in Vaccinology’ junior PI session and a career focus event illustrating opportunities beyond the purely academic career path.  During the COVID-19 pandemic she served as Co-chair for the ISV COVID-19 Vaccine Congress mini-series (2020 -2021). With Drs Shan Lu and Margaret Liu she wrote an article published in Emerging Microbes and Infections, which described the leadership role of the ISV in providing the global community with balanced presentations of progress and challenges in COVID-19 vaccine development.

Over the past 5 years she has annually contributed to the ISV as a workshop chair and as a plenary/workshop speaker. She regularly contributes to the ISV newsletters to publicise and feedback on the ISV’s work. She brings a trans European and North American perspective to the Society from her training and extensive research experience in several labs on these continents.   

ISV Fellow of the Month
Country
United Kingdom
Treasurer

Lenny Moise

Title
Director of Vaccine Research, EpiVax, Inc. and Research Professor, University of Georgia
Description

Lenny Moise, PhD, serves as the Vice President of Research at SeromYx Systems. He earned his PhD from the Department of Molecular and Cellular Biology and Biochemistry at Brown University in Providence, RI, in 2002. His doctoral research in Dr. Edward Hawrot’s laboratory focused on structure-function relationships of snake neurotoxin interactions with the nicotinic acetylcholine receptor. Following his PhD, Dr. Moise pursued postdoctoral training at Brown University, where he delved into the functional analysis of toxin binding sites engineered into toxin-insensitive ion channels. In 2005, he joined Dr. Anne De Groot’s laboratory at Brown University as an Instructor in Medicine in the Department of Medicine (Infectious Disease), where his research centered on T-cell epitope-driven vaccination and protein therapeutic immunogenicity. He joined EpiVax in Providence, RI, in 2006, where he served as the Director of Vaccine Research until 2022. Over this time, he led innovative T cell epitope-driven vaccine development projects, employing a comprehensive genomes-to-vaccine approach that combines immunoinformatic and immunologic methodologies. He also dedicated his efforts to the de-immunization of protein therapeutics through epitope modification. In 2008, Dr. Moise accepted a part-time appointment as Assistant Research Professor in the Department of Cell and Molecular Biology at the University of Rhode Island, becoming a founding faculty member of the URI Institute for Immunology and Informatics, and was promoted to Associate Research Professor in 2014. Additionally, from 2020 to 2022, he was a part-time Research Professor in the Center for Vaccines and Immunology at the University of Georgia. Dr. Moise joined SeromYx in 2022, where he assumed the responsibilities of driving the scientific development of the Systems Serology platform and overseeing the management of both commercial and internally driven research projects.

 

Secretary

Joon Haeng Rhee

Title
Professor of Microbiology, Chonnam National University Medical School
Description

Dr. Joon Haeng Rhee is a graduate of Chonnam National University Medical School and received PhD from the same university. He has been working on molecular microbial pathogenesis and vaccine biology for more than 30 years.

For the molecular microbial pathogenesis studies, his laboratory has been observing the V. vulnificus-host interactions using various molecular and cellular microbiological tools. His team was the first reporter of the whole genome sequence of V. vulnificus, which became one of the most widely used standard strains in the Vibrio research field. They identified an RTX (repeats in toxin) toxin as the culprit of deadly host-killing mechanism in the V. vulnificus infections and recently developed an effective preventive vaccine and therapeutic monoclonal antibody targeting a specific region of the toxin. Vaccine study was first started aiming the high mortality V. vulnificus infections. During the vaccine research, his team came across the finding that a flagellin protein of V. vulnificus has an excellent mucosal adjuvant effect in late 1990s, which was later proved by his group and others to be mediated by the TLR5 signaling. Currently his laboratory is studying the basic science and applications related to the flagellin-TLR5-mediated immune modulation. His team reported the mechanism how TLR5 is very well maintained in senescent animals and proposed that flagellin could be used an effective adjuvant for vaccines against infectious diseases affecting elderly population. Now flagellin is applied to the development of effective vaccines and immunotherapeutics against diverse diseases such as cancers, allergies, and Alzheimer’s disease.

He was the president of Korean Vaccine Society (KVS) from 2013 to 2015. He hosted the 2015 International Society for Vaccines (ISV) Congress in Seoul as a local co-chair. He was elected as an ISV Fellow and serves a member of ISV Executive Board. He served editorial board member for Infection and Immunity and Microbiology and Immunology journals. He is currently the director of Clinical Vaccine R&D Center and Combinatorial Tumor Immunotherapy Research Center of Chonnam National University. As of August 2021, he has more than 160 papers published in peer-reviewed journals and named as an inventor on 20 patents

ISV Fellow of the Month
Country
South Korea
President Elect

Manon Cox

Description

Dr. Manon M.J. Cox, MBA founded NextWaveBio early 2018 initially providing scientific and strategic direction to various biopharmaceutical companies. NextWaveBio’s mission is to bridge the gap between preclinical and clinical development by offering infrastructure and education around quality systems required for clinical development and manufacturing. Prior to that she led the development of Flublok®, the only FDA approved recombinant influenza vaccine at Protein Sciences Corporation where she served as President and Chief Executive Officer since April 2010 and Director since 2008. She joined Protein Sciences in 1998 as Director of Business Development and became Chief Operating Officer in 2003.

Previously she was with Gist-brocades, a large Dutch company specialized in fermentation, where she held various management positions, most recently in New Business Development and before that in Production and Research and Development.  Prior to joining Gist-brocades, she worked as a Molecular Biologist on the development of a PCR screening test for cervical cancer at the University of Amsterdam. 

She serves on the Board of Directors of Vaxxas, the Netherland-America Foundation including its Education Committee, the International Society of Vaccines, and various Scientific Advisory Boards in the vaccine development space.

Dr. Cox has received many honors and awards recognizing her stature as a leader in innovation and influenza, including in 2014 receiving a Doctorate in Humane Letters honoris causa from St. Joseph University and the Woman of Innovation award from the Connecticut Technology Council and was elected fellow in the International Society of Vaccines in 2015. Dr. Cox holds a Doctorate from the University of Wageningen, received her MBA with distinction from the University of Nyenrode and the University of Rochester, NY and holds a Doctorandus degree in Molecular Biology, Genetics and Biochemistry from the University of Nijmegen, The Netherlands.

ISV Fellow of the Month
Country
United States
Portraits
President Emeritus

Denise Doolan

Denise Doolan
ISV Fellow of the Month
Country
Australia
Portraits
Board Chairs

Linda Klavinskis

Title
Professor of Viral Immunology, King’s College London
Description

Linda S. Klavinskis, PhD, is Professor of Viral Immunology at King’s College London where her laboratory focuses on immunity to vaccination and virus infection. The goal is to understand and harness cross talk between dendritic cells and T cells, and use this knowledge to develop new and more effective vaccines. This work has led to deciphering an alternative mode of antigen presentation, termed ‘cross-dressing’ and unravelling mechanisms contributing to epitope selection and CD8 T-cell immunodominance. At the translational level, her lab has made contributions to the development of gene delivery systems for DNA and viral-mediated vaccination. More, recently she made inroads in understanding the biology of skin immunisation and developed a microneedle vaccine delivery platform. This has led to the new finding that skin immunisation activates cross talk with innate cells in epithelial barrier tissues to recruit effector CD8+ T-cells and can establish immune surveillance at the barrier tissues. During the COVID-19 pandemic her lab has focused on the role of innate immunity in the hyperinflammatory response in severe COVID-19 and applying therapeutic approaches. Her laboratory has co-authored over 100 peer-reviewed publications.

Professor Klavinskis currently serves as a member of the UK Medical Research Council’s Infection and Immunity Board. She also serves as Associate Editor of Frontiers in Mucosal Immunology and as an Editor of Frontiers in HIV and AIDS. She has served as President of the ‘Medical Research Club’, a prestigious London based biomedical society established 1891 with a focus in infection and immunity. She contributes to national and international peer review in vaccine sciences and as a consultant in industry. She has expertise in executive and senior management positions, including most recently as Vice Dean for Postgraduate Research (Life Sciences and Medicine) at King’s College London. She is a Fellow of the International Society for Vaccines and was elected a Fellow of the Royal College of Pathologists.

Linda Klavinskis has been an active member of the International Society for Vaccines since 2015 and is an elected ISV Fellow. Her service to the ISV includes, membership of the Executive Board since 2018 (where she has championed promoting opportunities for women and junior/early career researcher members in ISV activities); Secretary for the 2020-2021 term; and is President-elect for the 2022-2023 term.

She served as Co-Chair of the 2019 ISV Annual Congress in Ghent, playing a key role in identifying the Scientific Committee (SC) and planning the scientific program with the SC and also introduced further opportunities for junior researchers e.g. the “Bright Sparks in Vaccinology’ junior PI session and a career focus event illustrating opportunities beyond the purely academic career path.  During the COVID-19 pandemic she served as Co-chair for the ISV COVID-19 Vaccine Congress mini-series (2020 -2021). With Drs Shan Lu and Margaret Liu she wrote an article published in Emerging Microbes and Infections, which described the leadership role of the ISV in providing the global community with balanced presentations of progress and challenges in COVID-19 vaccine development.

Over the past 5 years she has annually contributed to the ISV as a workshop chair and as a plenary/workshop speaker. She regularly contributes to the ISV newsletters to publicise and feedback on the ISV’s work. She brings a trans European and North American perspective to the Society from her training and extensive research experience in several labs on these continents.   

ISV Fellow of the Month
Country
United Kingdom
Board Members

Neil Almond

Description

Neil Almond is Head of Diagnostics at the UK Medicines and Healthcare products Regulatory Agency (MHRA) at laboratories formerly known as NIBSC.  He directs a research team that develops laboratory animal model systems to establish the scientific basis of vaccine protection against high containment infectious disease.  This workplays a critical role in  informing funders, developers and regulators in decision making regarding vaccine development and also guides the development of physical measurement standards including WHO established International Standards that assure the quality of biological medicines worldwide.

Neil’s research is focused on WHO priorities of emerging diseases, especially Zika, Chikungunya, Lassa Fever and Crimean Congo Haemorrhagic Fever viruses as well as Plague and Q Fever to establish serological correlates of immune protection.  He is also recognised as a leader in the vaccine field applying the SIV models to inform vaccine selection and development. Importantly, his responsibilities also include the development of reference materials that assure the quality of serological and molecular diagnostic assays that are used in the diagnosis and treatment of infection and inform vaccine use.

 Neil chairs the organising committee of the meeting Standardisation of Genome Amplification Techniques and Serology (SoGATS) that meets biannually to advise the WHO Expert Committee on the development of physical reference standards that underpin measurement in infectious disease.  He is a member of the UK National Blood Service Joint Professional Advisory Committee that provides strategic direction to the provision of safe blood in the UK.  Neil also sits on the Nucleic Acid Working Group of the Consultative Committee for Amount of Substance: Metrology in Chemistry and Biology (CCQM) as well as the Bureau International de Poids et Mesures (BIPM)-International Federation of Clinical Chemistry and Laboratory Medicine Joint Committee for the Traceabilty of Laboratory Medicines Review Team for Nucleic Acids.

Neil has been a member of Grant review Board for the UK Research and Innovation Proactive Vaccinology and the review panel of the UK’s National Institute for Health Research Policy Research Programme for vaccination.  He has previously been an invited review panel member for NIH programmes funding simian models of HIV/AIDS.

At NIBSC Neil was appointed the youngest Head of a Scientific Division, when he took responsibility for the Division of Retrovirology in 1998.  He was a member of NIBSC’s Senior Management Team for 22 years, during which time he chaired the Finance, Human Resources and Facilities sub-committee.  He has chaired the Research Programme Board for the past 10 years and led on and managed successful applications for programme grant funding from UK Department of Health and Social Care for the Regulatory Science Research Unit at the South Mimms Laboratories addressing regulatory scientific research needs across all aspects of Biological Medicines (vaccines, bio-therapeutics, gene and cell therapeutics and diagnostics)   

ISV Fellow of the Month
Country
United States

Danilo Casimiro

Description

Danilo is Chief Science Officer and Global Head, External Scientific Affairs for Sanofi Vaccines since October 2021.  He is responsible for several external-facing functions of the Vaccines R&D unit, including teams for search-and-evaluation of vaccine candidates and vaccine innovations, scientific network development & partnerships, and external financing.  More recently, he contributed to several business development projects including the recent acquisition of Translate Bio/USA and ORIGIMM/Austria by Sanofi.  He has over 25 years of experience in research and development of vaccines and biologics in both pharmaceutical and non-profit sectors.  Prior to joining Sanofi in November 2017, he was the Chief Scientific Officer at Aeras, a non-profit vaccine R&D organization funded by the Bill and Melinda Gates Foundation. During his 19 years at the Merck Research Laboratories, Danilo contributed to the licensure of Merck’s human papillomavirus (HPV) vaccines, and the development of novel vaccine candidates and antibodies against multiple viral pathogens and novel immunotherapeutic approaches against cancer and neurodegenerative diseases.  He also currently serves on several advisory committees such as BMGF-NIH Clinical AIDS Vaccine Development Program, USAID Malaria Vaccine Development Program, and the WHO mRNA Scientific Advisory Board. He received his B.S. in chemistry from the University of the Philippines, and his Ph.D. degree in chemistry/biochemistry and post-doctoral training from the California Institute of Technology and the Scripps Research Institute-La Jolla, respectively.

 

ISV Fellow of the Month
Country
United States

Lakshmi Krishnan

Description

Dr. Lakshmi Krishnan is the Vice-President of Life Sciences at the National Research Council, Canada (NRC). In this capacity, she oversees the Human Health Therapeutics, Aquatic and CropResource Development and Medical Devices research centers. She previously held the position of Director General for NRC-Human Heath Therapeutics Research Centre (2019-2021) and Director of NRC-Program in Vaccines & Immunotherapy (2015-2018).
As a globally recognized Life Sciences researcher, Dr. Krishnan has been a leader for driving innovation in the area of novel vaccines and biologics treatments for the improvement of human health. In her current role Dr. Krishnan is committed to Health technologies & Biomanufacturing Innovation and sustainable bio-economy.

Dr. Krishnan is member of a number of national, international and inter-governmental forums such as the Canadian Cancer Research Alliance, the National Synthetic Biology Steering Committee, CIHR’s Centre for research on Pandemic Preparedness & Health Emergencies, Government of Canada Life Sciences and Biomanufacturing Assistant-Deputy Ministers’ Committee and Canada Biomedical Research Fund Hubs Governance Committees. Previously, as Director General (DG) at the NRC she co-chaired the DG level-Vaccine Research Innovation & Development Committee which brought together 13-federal Canadian S&T departments to enable collaboration and co-innovation for vaccine development. She is the current Canadian Co-Chair, under the “Canada-South Korea Agreement on Science, Technology and Innovation” as well as the NRC representative at government of Canada international joint committees and has been an invited guest speaker in various international conferences.

Dr. Krishnan holds a Master's degree in Bio-medical Genetics from the University of Madras (India) and a Ph.D. in Immunology from the National Institute of Immunology in India. She completed her Post-Doctoral training at the University of Alberta and was a recipient of the Alberta Heritage Foundation Health Research Scholarship. Dr. Krishnan has published over 100 primary research articles in peer-reviewed journals primarily in the area of vaccine adjuvants and immunity to infection and is listed as an inventor on several patents on adjuvant technologies. She serves as an Adjunct Professor in the Department of Biochemistry, Microbiology and Immunology at the University of Ottawa and has mentored many graduate students.

In her free time, she volunteers with several not-for-profit organizations mentoring youth leadership skills and to pursue STEM careers.

ISV Fellow of the Month
Country
United States

Margaret Liu

Description

Professor Margaret A. Liu, obtained an M.D. from Harvard Medical School, a B.A. in Chemistry, summa cum laude, from Colorado College, and passed the Epreuve pour le Diplôme d’Enseignement, à l’unanimité (judges’ unanimous decision), in piano from the Ecole Normale de Musique de Paris, and is the recipient of an honorary Medical Degree (MD honoris causa) from the Karolinska Institutet in Stockholm, and an honorary Doctorate of Science from Colorado College. She completed Internship and Residency in Internal Medicine and a Fellowship in Endocrinology, all at Massachusetts General Hospital/Harvard Medical School. She received Board Certification in Internal Medicine and in Endocrinology and Metabolism. Dr. Liu was a Visiting Scientist at the Massachusetts Institute of Technology, Instructor at Harvard Medical School, Adjunct Assistant Professor of Medicine at the University of Pennsylvania, a Visiting Professor at the Karolinska Institutet in Stockholm, and the recipient of an NIH Physician Scientist Award. She served as Senior Director at Merck Research Laboratories, Vice President of Vaccines Research and Gene Therapy at Chiron Corporation, Vice-Chairman of Transgène, Senior Advisor in Vaccinology at the Bill & Melinda Gates Foundation, Executive Vice-Chair of the International Vaccine Institute, and was on the US NIH NIAID Council.

Her research has focused on novel technologies for vaccines and immune treatments for cancer. She pioneered the development of DNA vaccines, which are now in clinical trials for many human diseases and are licensed for several veterinary applications. She also was an innovator in the field of bispecific antibodies to activate T cells for tumor cell killing. The Nobel Committee invited her to lecture in the Karolinska Research Lecture series, and she was named by Discover magazine as one of the 50 most important female scientists. She consults world-wide for companies, investment firms, non-governmental organizations, and governmental scientific advisory bodies, and has held positions as an Adjunct Professor at UCSF, and as a Foreign Adjunct Professor at the Karolinska Institutet. Dr. Liu was previously the President of the International Society for Vaccines for the 2015- 2017 term, then President Emerita, and is currently the Chairman of the Board of ISV (2020-2021).

ISV Fellow of the Month
Country
United States
Portraits

Shan Lu

ISV Fellow of the Month
Country
United States
Portraits

Megan Polidano

Description

Megan joined Vaxxas Pty Ltd as the Head of Clinical Research and Regulatory Affairs in March 2021. She is responsible for the clinical development of Vaxxas product portfolio and for overseeing the regulatory affairs function with the company. Megan has over 20 years of experience working in this area and is passionate about the translation of novel research into commercialized therapeutic products that can make a difference to people’s lives.

Megan started her regulatory affairs career at CSL, working on novel vaccine technologies and was responsible for managing the registration of seasonal Influenza vaccine across Europe. At CSL, she also managed their in-licensed vaccine portfolio. Throughout her career she has been responsible for the development of regulatory and clinical strategy, maintenance of product registration and for registering new medicines and medical devices across a broad range of therapeutics areas. Megan has held senior regulatory and clinical roles in both the pharmaceutical and medical device companies including PolyNovo, Pfizer and LEO Pharma and has also spent time working as a consultant. Prior to joining Vaxxas, Megan was a Senior Project Manager at QBiotics developing a novel topical wound healing product.

Megan obtained an undergraduate degree (with Honours) in Applied Biology/Biotechnology from the Royal Melbourne Institute of Technology and a Ph.D degree from the Department of Biochemistry and Molecular Biology at the University of Melbourne. She also completed post-doctoral research at Cognetix Inc (Salt Lake City).

ISV Fellow of the Month
Country
United States

Ed Rybicki

Description

Dr. Ed Rybicki is a four-time graduate of the University of Cape Town (UCT) who trained as a plant virologist/biotechnologist, but who has for over 25 years worked in the field of vaccinology. Since the mid-1990s he has been involved largely in research on the production of human and animal candidate vaccine an3gens, mainly in plants, but also in insect cells and bacteria. He has been the Director of the Biopharming Research Unit at UCT since its incep3on in 2013: this group has been one of the leading “molecular farming” groups in the world for nearly 20 years. Highlights include production in insect cells and later in plants of HIV subtype C Gag virus-like par3cles (VLPs) as part of the South African AIDS Vaccine Ini3a3ve, and more recently making trimeric HIV-1 C gp140Env in plants; pioneering the plant produc3on of HPV L1-based par3cles, and of the H5N1 HPAI haemagglu3nin – both of which were licenced to industry – and making VLPs in plants for both bluetongue and African horse sickness orbiviruses, with successful proofs of concept as vaccines in target animals. He is presently collaborating on South African Medical Research Council (SAMRC) Strategic Health Innovations Partnerships projects on HIV protein- and DNA-based vaccines.

Dr. Rybicki is a named inventor on the largest vaccine-related patent portfolio in Africa – 17 patent families – and has published more than 230 research articles, 122 of them on vaccines. A successful molecular farming company making reagents in plants – Cape Bio Pharms Ltd. –
was spun out in Cape Town from UCT in 2015 based on the BRU’s product portfolio. Dr. Rybicki was a consultant to several South African governmental groups on SARS-CoV-2 vaccines during the early pandemic. He is also a major contributor to the international popularization of virology and of vaccines on social media. He recently (February 2023) published a revision of Alan Cann’s Principles of Molecular Virology for a 7th Edition, for Elsevier’s Academic Press.

ISV Fellow of the Month
Country
United States

Xavier Saelens

Title
Professor of Biochemistry and Microbiology, Ghent University
Description

Dr. Xavier Saelens obtained his PhD degree from the University of Ghent (Ghent, Belgium) in 1990 in the laboratory of Walter Fiers. After postdoctoral training in the influenza research group of Willy Min Jou, and in the Molecular Signaling and Cell Death group of Peter Vandenabeele, both at Ghent University, he became an assistant professor in Molecular Virology in 2008. Currently, he is a full professor in the Department of Biochemistry and Microbiology at Ghent University and a principle investigator at the VIB-UGent Center for Medical Biotechnology.

The research team of Xavier Saelens applies modern biotechnology methods to develop new vaccines and antivirals against important human respiratory viruses such as influenza, respiratory syncytial virus and, more recently, coronaviruses. In addition, his group uses interactomics tools to gain new insights in the molecular interplay between host and viral factors.

His research group pioneered the development of a universal influenza A vaccine candidate based on the viral matrix protein 2 and elucidated it’s mechanism of protection. More recently, his team proposed a new human respiratory syncytial vaccine candidate that is based on the small hydrophobic protein of this virus. This vaccine candidate has successfully passed a Phase I clinical study. The group also develops single domain antibodies and formats thereof as new candidate biologics to control infections by human respiratory viruses. A recently started research focus point is the development of respiratory delivery technologies for antibody-based antivirals.

In 2015 he received the biennial price in Virology from the Study Centre Princess Joséphine- Charlotte from the Flanders and Walloon Research Foundations of Belgium. In 2019 and 2020 Xavier Saelens obtained excellence awards from VIB for outstanding scientific and technology transfer output.

He is a board member and the treasurer of the Belgian Society for Microbiology and member of the board of the International Society for Vaccines where he has contributed in many ways to the society.

ISV Fellow of the Month
Country
Belgium

Jeffrey Ulmer

Description

Dr. Jeffrey Ulmer has been an active scientist in the vaccines community since completing his post-doctoral fellowship in 1990.  He has published more than 200 scientific papers in various aspects of vaccines discovery and development, is named as a co-inventor on eleven patents, serves on the editorial boards of three journals, and has been on the scientific advisory boards of many academic laboratories and biotechnology companies.  During his career in the vaccines industry, he has held scientific and management positions in the Vaccines divisions of Merck Research Laboratories, Chiron Corporation, Novartis and GSK.  His various leadership roles and responsibilities have included:  Platform Technology Leader (DNA, RNA vaccines), Project Leader (Tuberculosis, SARS); Department Head (Immunology & Cell Biology), Global Function Head (External Research), US Site Head Research, Head Preclinical R&D, and Program Head Technical R&D.

ISV Fellow of the Month
Country
United States

David Weiner

Title
Director, Vaccine and Immunotherapy Center and Executive Vice President, Wistar Institute; Professor Emeritus, University of Pennsylvania
Description

Dr. David B. Weiner directs a translational molecular immunology research team focused on synthetic nucleic acid-based approaches for disease prevention and treatment.  His group is one of the first research teams in the field of Nucleic Acid Vaccines & Immune Therapies, advancing some of their first clinical trials.  His lab has contributed to multiple aspects and technology developments in advancing DNA vaccines.  Work resulted in clinical studies of an early Zika vaccine, the first MERS vaccine, an advanced Ebola Vaccine, a SARS-CoV2 Vaccine and a novel HIV immunogen platform, among others in the infectious disease arena.  In oncology his laboratory has helped to advance novel immune therapy approaches for HPV disease, prostate disease, GMB immunotherapy which are in clinical testing. This year a therapeutic DNA vaccine (HPV CIN) (VGX3100) moved into a licensure trial (REVEAL).  His lab work is also advancing dMAb in vivo antibody technologies for immune prevention and therapy.

Dr. Weiner’s laboratory has published over 430 papers/chapters & reviews and provided > 450 lectures. He has received several awards/honors, including the WW Smith Family Chair in Cancer Research - 2016, Vaccine Industry Association Outstanding Academic Research Laboratory (2015 & 2016) (runner up 2017, 2018, 2019), Top 20 Translational Research Laboratories of the Year (Nature Biotechnology 2016 - 2020), Stone family award for Cancer Research 2014, NIH Directors Translational Research Award 2011, and the Pennsylvania Life Sciences Achievement Award (2019). He is a Fellow of the American Association for the Advancement of Science 2011 and a Fellow of the International Society for Vaccines 2010.  He served as President of the International Society for Vaccines (2018-2020).  He serves on the Executive Committee of the UPENN CFAR and served as chair of the prestigious Gene Therapy and Vaccine Training Program at the University of Pennsylvania (2004-2016).  He is currently a Wistar Institute Professor, Director of the Vaccine and Immunotherapy Center and the Executive Vice President of the Wistar Institute, and a Professor Emeritus at the University of Pennsylvania.   Dr. Weiner has been an avid teacher, trainer, advisor, and advocate for students, fellows and junior faculty as he is highly committed to developing of the careers of young scientists.  

ISV Fellow of the Month
Country
United States